Navigation Links
Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
Date:4/21/2009

Abstract #4061

DENVER, April 21 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data today at the American Association for Cancer Research's 100th Annual Meeting 2009 that could potentially provide a brighter future for children who suffer from a more deadly form of acute leukemia.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSLOGO)

Yubin Ge, Ph.D., and Chengzhi Xie, Ph.D., presented a poster at the conference revealing that a combination of FDA-approved drugs works synergistically to help children with acute myeloid leukemia (AML). Dr. Ge is an Assistant Professor at the Karmanos Cancer Institute and at the Wayne State University School of Medicine's Department of Pediatrics. Dr. Xie is a Postdoctoral Fellow with the Developmental Therapeutics Program at Karmanos Cancer Institute and Wayne State University School of Medicine. He also is a lecturer with the College of Life Science at Jilin University in Changchun, China.

AML, which originates in bone marrow, accounts for one-fourth of acute leukemia in children and is responsible for more than half of the leukemia deaths in this population. Approximately 600 children are diagnosed with AML each year, according to Dr. Ge and presently there is no effective drug treatment for those children should they relapse.

"Right now, we are at a bottleneck," Dr. Ge said. "We really want to find a better treatment for those relapsed cases."

Dr. Ge and fellow researchers considered drugs that are already FDA-approved to help fight AML. Resistance among patients to FDA-approved cytarabine is a major cause of treatment failure in AML. Scientists considered clofarabine, approved by the FDA in 2004, and paired it with valproic acid (VPA), typically used to treat epilepsy. They found the two drugs worked together to dramatically stimulate cell death.

"We considered an old drug for a new use," Dr. Ge said. "It looks like the increased drug activity or synergy is not due to the transport or delivery of clofarabine, but to enhanced cell death. We were so pleased with the results."

AML afflicts mostly adults -- about 10,000 new cases each year -- and strikes older children. Acute lymphoblastic leukemia usually affects children between the ages of 2 to 5 and is generally easier to treat. Treatment advancements for AML, however, have been less successful.

Dr. Ge said researchers at Karmanos discovered the synergy between VPA and clofarabine only a few months ago, though departmental research has spanned some 15 years in the field of treating childhood leukemias. The current research represents a unique partnership between Dr. Ge, his Karmanos colleagues, and Jeffrey W. Taub, M.D., a pediatric oncologist at Children's Hospital of Michigan, also in Detroit.

Dr. Ge expects that their findings will move into the clinical phase in the next few years. St. Jude Children's Research Hospital in Memphis, Tenn. Is now conducting its own clinical drug trial studying the combined effects of VPA and cytarabine to treat newly diagnosed AML patients 21 years old and younger.

"This is truly translational research," Dr. Ge said. "We really want to translate what we do in the laboratory to the clinic and hopefully save more lives."

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. For more information call 1-800-KARMANOS or go to www.karmanos.org.


'/>"/>
SOURCE Barbara Ann Karmanos Cancer Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
2. DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers
3. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
4. Karmanos Cancer Institute Researchers Show Phase I Immunotherapy with Armed T Cells Improve Overall Survival of Metastatic Breast Cancer Patients
5. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
6. Karmanos Researchers Study the Impact of Galectin-3 on Breast Cancer Disparity in Caucasian and Asian Women
7. Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells
8. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Genes Identified That Enhance Tumor Cell Sensitivity to CTIs Cancer Drug Brostallicin
11. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology:
(Date:2/11/2016)... Viejo, CA (PRWEB) , ... February 11, 2016 , ... ... Pro X users with customizable backdrops in the Christmas edition of the ProDrop ... of the year. Captivate audiences and invoke the spirit of Christmas using ProDrop's wintry ...
(Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... expand dental health services to the developmentally disabled in the Coachella Valley. , ... to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho Mirage, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group ... associations of medical professionals throughout the country. The Guard was specifically designed to ... and procedures, employee training, regulatory updates, and compliance coaching. , In addition to ...
Breaking Medicine News(10 mins):